

# **Pancreatic Cancer Diagnostic Market By Product (Instruments, Consumables), By Test Type (Imaging Test, Blood Test, Biopsy), By Cancer Type (Exocrine, Endocrine), By End User (Hospitals, Diagnostic Centers, Others): Global Opportunity Analysis and Industry Forecast, 2024-2035**

<https://marketpublishers.com/r/P16AE735A872EN.html>

Date: March 2025

Pages: 368

Price: US\$ 2,655.00 (Single User License)

ID: P16AE735A872EN

## **Abstracts**

The pancreatic cancer diagnostic market was valued at \$1.6billion in 2023 and is estimated to reach \$3.2billion by 2035, exhibiting a CAGR of 5.9% from 2024 to 2035. Pancreatic cancer diagnostics involves the identification and confirmation of pancreatic cancer through various medical techniques and tools. This process typically begins with a detailed review of the patient's medical history and symptoms, followed by physical examinations and imaging tests such as computed tomography (CT), magnetic resonance imaging (MRI), or endoscopic ultrasound (EUS). These imaging modalities help visualize abnormalities in the pancreas and surrounding tissues. In addition, blood tests may be conducted to detect biomarkers such as CA 19-9, a protein often elevated in pancreatic cancer patients. Biopsies obtained through fine-needle aspiration or surgical procedures provide a definitive diagnosis by allowing microscopic examination of pancreatic tissue for cancerous cells. Early and accurate diagnosis is critical for guiding treatment decisions and improving patient outcomes.

The pancreatic cancer diagnostic market is driven by increase in prevalence of pancreatic cancer, advancements in diagnostic technologies, rise in awareness about early detection, and rise in demand for non-invasive diagnostic techniques. Pancreatic cancer, known for its aggressive nature and poor prognosis, is one of the leading causes of cancer-related deaths globally. Rise in incidence of pancreatic cancer, coupled with lack of effective early diagnostic methods, has created a significant need

for innovative diagnostic solutions. In addition, rise in technological advancements in imaging techniques such as computed tomography (CT), magnetic resonance imaging (MRI), and endoscopic ultrasound (EUS), have enhanced the ability to detect pancreatic tumors at earlier stages, thereby supporting the market growth. These imaging modalities offer high-resolution images that enable clinicians to identify pancreatic abnormalities with greater accuracy. The advent of more advanced tools, such as molecular imaging and liquid biopsy, is also contributing to the market growth by allowing for earlier detection and improved patient monitoring.

Furthermore, traditional diagnostic methods such as surgical biopsies are often associated with higher risks and recovery times, leading to a shift toward non-invasive techniques like blood tests, urine tests, and liquid biopsy, which drives the market growth. Liquid biopsy, which analyzes blood or other bodily fluids for cancer-related biomarkers, is emerging as a promising tool for diagnosing pancreatic cancer, as it reduces the need for more invasive procedures while providing valuable molecular insights.

Rise in awareness of pancreatic cancer and the importance of early detection is also fueling the market growth. Awareness campaigns, along with better access to healthcare services, have contributed to rise in screening and diagnostic procedures. Governments, healthcare organizations, and advocacy groups are focusing on educating the public about signs and symptoms of pancreatic cancer, emphasizing the significance of early diagnosis in improving survival rates.

However, high cost of advanced diagnostic technologies, such as molecular testing and imaging techniques, can limit accessibility, particularly in low-income regions. In addition, lack of specialized healthcare infrastructure and trained medical professionals in certain areas hinders the effective implementation and use of these diagnostic tools. On the other hand, rise in focus of government and healthcare organizations on early cancer detection creates a favorable environment for the adoption of advanced diagnostic tools. Expanding healthcare infrastructure in emerging markets, particularly in LAMEA, opens up new avenues for introducing cutting-edge diagnostic technologies.

The pancreatic cancer diagnostic market is segmented into product, test type, cancer type, end user, and region. By product, the market is segregated into instruments and consumables. By test type, the market is categorized into imaging test, blood test, and biopsy. By cancer type, the market is classified into exocrine and endocrine. The exocrine segment is further categorized into adenocarcinoma, adenosquamous carcinoma, colloid carcinoma, and others. By end user, the market is classified into

hospitals and clinics, diagnostic centers, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA).

Major players that operate in the pancreatic cancer diagnostic market are Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, Randox Laboratories Ltd., Prestige Biopharma Ltd., Siemens, ClearNote Health, Qiagen N.V., Toray Industries, Inc., and Myriad Genetics, Inc. Key players have adopted product launch, agreement, collaboration, and product approval as key developmental strategies to improve the product portfolio of the pancreatic cancer diagnostic market.

### **Key Benefits for Stakeholders**

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pancreatic cancer diagnostic market analysis from 2023 to 2035 to identify the prevailing pancreatic cancer diagnostic market opportunities.

The market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the pancreatic cancer diagnostic market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global pancreatic cancer diagnostic market trends, key players, market segments, application areas, and market growth strategies.

**Additional benefits you will get with this purchase are:**

Quarterly Update and\* (only available with a corporate license, on listed price)

5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

Free Upcoming Version on the Purchase of Five and Enterprise User License.

16 analyst hours of support\* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

15% Free Customization\* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)

Free data Pack on the Five and Enterprise User License. (Excel version of the report)

Free Updated report if the report is 6-12 months old or older.

24-hour priority response\*

Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines

Additional company profiles with specific to client's interest

Additional country or region analysis- market size and forecast

Average Selling Price Analysis / Price Point Analysis

Expanded list for Company Profiles

Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Volume Market Size and Forecast

## **Key Market Segments**

### By Product

Instruments

Consumables

Type

kits

Needles

Others

### By Test Type

Blood Test

Biopsy

Imaging Test

### By Cancer Type

Exocrine

Type

Adenocarcinoma

Adenosquamous Carcinoma

Others

Endocrine

By End User

Hospitals

Diagnostic Centers

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

UK

Italy

Spain

Rest of Europe

Asia-Pacific

Japan

China

India

Australia

South Korea

Rest of Asia-Pacific

LAMEA

Brazil

Saudi Arabia

South Africa

Rest of LAMEA

Key Market Players

F. Hoffmann-La Roche Ltd.

Fujifilm Holdings Corporation

Prestige Biopharma Ltd.

Siemens

ClearNote Health

Toray Industries, Inc.

Myriad Genetics, Inc.

Thermo Fisher Scientific Inc.

Randox Laboratories Ltd.

Qiagen N.V.

## Contents

### **CHAPTER 1: INTRODUCTION**

- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research methodology
  - 1.4.1. Primary research
  - 1.4.2. Secondary research
  - 1.4.3. Analyst tools and models

### **CHAPTER 2: EXECUTIVE SUMMARY**

- 2.1. CXO perspective

### **CHAPTER 3: MARKET OVERVIEW**

- 3.1. Market definition and scope
- 3.2. Key findings
  - 3.2.1. Top impacting factors
  - 3.2.2. Top investment pockets
- 3.3. Porter's five forces analysis
  - 3.3.1. Moderate bargaining power of suppliers
  - 3.3.2. Moderate threat of new entrants
  - 3.3.3. Moderate threat of substitutes
  - 3.3.4. Moderate intensity of rivalry
  - 3.3.5. Moderate bargaining power of buyers
- 3.4. Market dynamics
  - 3.4.1. Drivers
    - 3.4.1.1. Increase in incidence of pancreatic cancer
    - 3.4.1.2. Technological advancements in diagnostics
    - 3.4.1.3. Growing awareness and early detection initiatives
  - 3.4.2. Restraints
    - 3.4.2.1. High diagnostic cost
  - 3.4.3. Opportunities
    - 3.4.3.1. High growth potential in emerging countries

### **CHAPTER 4: PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT**

*Pancreatic Cancer Diagnostic Market By Product (Instruments, Consumables), By Test Type (Imaging Test, Blood T...*

#### 4.1. Overview

##### 4.1.1. Market size and forecast

#### 4.2. Instruments

##### 4.2.1. Key market trends, growth factors and opportunities

##### 4.2.2. Market size and forecast, by region

##### 4.2.3. Market share analysis by country

#### 4.3. Consumables

##### 4.3.1. Key market trends, growth factors and opportunities

##### 4.3.2. Market size and forecast, by region

##### 4.3.3. Market share analysis by country

##### 4.3.4. Consumables Pancreatic Cancer Diagnostic Market by Type

###### 4.3.4.1. kits Market size and forecast, by region

###### 4.3.4.2. kits Market size and forecast, by country

###### 4.3.4.3. Needles Market size and forecast, by region

###### 4.3.4.4. Needles Market size and forecast, by country

###### 4.3.4.5. Others Market size and forecast, by region

###### 4.3.4.6. Others Market size and forecast, by country

### **CHAPTER 5: PANCREATIC CANCER DIAGNOSTIC MARKET, BY TEST TYPE**

#### 5.1. Overview

##### 5.1.1. Market size and forecast

#### 5.2. Imaging Test

##### 5.2.1. Key market trends, growth factors and opportunities

##### 5.2.2. Market size and forecast, by region

##### 5.2.3. Market share analysis by country

#### 5.3. Blood Test

##### 5.3.1. Key market trends, growth factors and opportunities

##### 5.3.2. Market size and forecast, by region

##### 5.3.3. Market share analysis by country

#### 5.4. Biopsy

##### 5.4.1. Key market trends, growth factors and opportunities

##### 5.4.2. Market size and forecast, by region

##### 5.4.3. Market share analysis by country

### **CHAPTER 6: PANCREATIC CANCER DIAGNOSTIC MARKET, BY CANCER TYPE**

#### 6.1. Overview

- 6.1.1. Market size and forecast
- 6.2. Exocrine
  - 6.2.1. Key market trends, growth factors and opportunities
  - 6.2.2. Market size and forecast, by region
  - 6.2.3. Market share analysis by country
  - 6.2.4. Exocrine Pancreatic Cancer Diagnostic Market by Type
    - 6.2.4.1. Adenocarcinoma Market size and forecast, by region
    - 6.2.4.2. Adenocarcinoma Market size and forecast, by country
    - 6.2.4.3. Adenosquamous Carcinoma Market size and forecast, by region
    - 6.2.4.4. Adenosquamous Carcinoma Market size and forecast, by country
    - 6.2.4.5. Others Market size and forecast, by region
    - 6.2.4.6. Others Market size and forecast, by country
- 6.3. Endocrine
  - 6.3.1. Key market trends, growth factors and opportunities
  - 6.3.2. Market size and forecast, by region
  - 6.3.3. Market share analysis by country

## **CHAPTER 7: PANCREATIC CANCER DIAGNOSTIC MARKET, BY END USER**

- 7.1. Overview
  - 7.1.1. Market size and forecast
- 7.2. Hospitals
  - 7.2.1. Key market trends, growth factors and opportunities
  - 7.2.2. Market size and forecast, by region
  - 7.2.3. Market share analysis by country
- 7.3. Diagnostic Centers
  - 7.3.1. Key market trends, growth factors and opportunities
  - 7.3.2. Market size and forecast, by region
  - 7.3.3. Market share analysis by country
- 7.4. Others
  - 7.4.1. Key market trends, growth factors and opportunities
  - 7.4.2. Market size and forecast, by region
  - 7.4.3. Market share analysis by country

## **CHAPTER 8: PANCREATIC CANCER DIAGNOSTIC MARKET, BY REGION**

- 8.1. Overview
  - 8.1.1. Market size and forecast By Region
- 8.2. North America

- 8.2.1. Key market trends, growth factors and opportunities
- 8.2.2. Market size and forecast, by Product
  - 8.2.2.1. North America Consumables Pancreatic Cancer Diagnostic Market by Type
- 8.2.3. Market size and forecast, by Test Type
- 8.2.4. Market size and forecast, by Cancer Type
  - 8.2.4.1. North America Exocrine Pancreatic Cancer Diagnostic Market by Type
- 8.2.5. Market size and forecast, by End User
- 8.2.6. Market size and forecast, by country
  - 8.2.6.1. U.S.
    - 8.2.6.1.1. Market size and forecast, by Product
      - 8.2.6.1.1.1. U.S. Consumables Pancreatic Cancer Diagnostic Market by Type
    - 8.2.6.1.2. Market size and forecast, by Test Type
    - 8.2.6.1.3. Market size and forecast, by Cancer Type
      - 8.2.6.1.3.1. U.S. Exocrine Pancreatic Cancer Diagnostic Market by Type
    - 8.2.6.1.4. Market size and forecast, by End User
  - 8.2.6.2. Canada
    - 8.2.6.2.1. Market size and forecast, by Product
      - 8.2.6.2.1.1. Canada Consumables Pancreatic Cancer Diagnostic Market by Type
    - 8.2.6.2.2. Market size and forecast, by Test Type
    - 8.2.6.2.3. Market size and forecast, by Cancer Type
      - 8.2.6.2.3.1. Canada Exocrine Pancreatic Cancer Diagnostic Market by Type
    - 8.2.6.2.4. Market size and forecast, by End User
  - 8.2.6.3. Mexico
    - 8.2.6.3.1. Market size and forecast, by Product
      - 8.2.6.3.1.1. Mexico Consumables Pancreatic Cancer Diagnostic Market by Type
    - 8.2.6.3.2. Market size and forecast, by Test Type
    - 8.2.6.3.3. Market size and forecast, by Cancer Type
      - 8.2.6.3.3.1. Mexico Exocrine Pancreatic Cancer Diagnostic Market by Type
    - 8.2.6.3.4. Market size and forecast, by End User
- 8.3. Europe
  - 8.3.1. Key market trends, growth factors and opportunities
  - 8.3.2. Market size and forecast, by Product
    - 8.3.2.1. Europe Consumables Pancreatic Cancer Diagnostic Market by Type
  - 8.3.3. Market size and forecast, by Test Type
  - 8.3.4. Market size and forecast, by Cancer Type
    - 8.3.4.1. Europe Exocrine Pancreatic Cancer Diagnostic Market by Type
  - 8.3.5. Market size and forecast, by End User
  - 8.3.6. Market size and forecast, by country
    - 8.3.6.1. Germany

- 8.3.6.1.1. Market size and forecast, by Product
  - 8.3.6.1.1.1. Germany Consumables Pancreatic Cancer Diagnostic Market by Type
- 8.3.6.1.2. Market size and forecast, by Test Type
- 8.3.6.1.3. Market size and forecast, by Cancer Type
  - 8.3.6.1.3.1. Germany Exocrine Pancreatic Cancer Diagnostic Market by Type
- 8.3.6.1.4. Market size and forecast, by End User
- 8.3.6.2. France
  - 8.3.6.2.1. Market size and forecast, by Product
    - 8.3.6.2.1.1. France Consumables Pancreatic Cancer Diagnostic Market by Type
  - 8.3.6.2.2. Market size and forecast, by Test Type
  - 8.3.6.2.3. Market size and forecast, by Cancer Type
    - 8.3.6.2.3.1. France Exocrine Pancreatic Cancer Diagnostic Market by Type
  - 8.3.6.2.4. Market size and forecast, by End User
- 8.3.6.3. UK
  - 8.3.6.3.1. Market size and forecast, by Product
    - 8.3.6.3.1.1. UK Consumables Pancreatic Cancer Diagnostic Market by Type
  - 8.3.6.3.2. Market size and forecast, by Test Type
  - 8.3.6.3.3. Market size and forecast, by Cancer Type
    - 8.3.6.3.3.1. UK Exocrine Pancreatic Cancer Diagnostic Market by Type
  - 8.3.6.3.4. Market size and forecast, by End User
- 8.3.6.4. Italy
  - 8.3.6.4.1. Market size and forecast, by Product
    - 8.3.6.4.1.1. Italy Consumables Pancreatic Cancer Diagnostic Market by Type
  - 8.3.6.4.2. Market size and forecast, by Test Type
  - 8.3.6.4.3. Market size and forecast, by Cancer Type
    - 8.3.6.4.3.1. Italy Exocrine Pancreatic Cancer Diagnostic Market by Type
  - 8.3.6.4.4. Market size and forecast, by End User
- 8.3.6.5. Spain
  - 8.3.6.5.1. Market size and forecast, by Product
    - 8.3.6.5.1.1. Spain Consumables Pancreatic Cancer Diagnostic Market by Type
  - 8.3.6.5.2. Market size and forecast, by Test Type
  - 8.3.6.5.3. Market size and forecast, by Cancer Type
    - 8.3.6.5.3.1. Spain Exocrine Pancreatic Cancer Diagnostic Market by Type
  - 8.3.6.5.4. Market size and forecast, by End User
- 8.3.6.6. Rest of Europe
  - 8.3.6.6.1. Market size and forecast, by Product
    - 8.3.6.6.1.1. Rest of Europe Consumables Pancreatic Cancer Diagnostic Market by Type
  - 8.3.6.6.2. Market size and forecast, by Test Type

8.3.6.6.3. Market size and forecast, by Cancer Type

8.3.6.6.3.1. Rest of Europe Exocrine Pancreatic Cancer Diagnostic Market by Type

8.3.6.6.4. Market size and forecast, by End User

#### 8.4. Asia-Pacific

8.4.1. Key market trends, growth factors and opportunities

8.4.2. Market size and forecast, by Product

8.4.2.1. Asia-Pacific Consumables Pancreatic Cancer Diagnostic Market by Type

8.4.3. Market size and forecast, by Test Type

8.4.4. Market size and forecast, by Cancer Type

8.4.4.1. Asia-Pacific Exocrine Pancreatic Cancer Diagnostic Market by Type

8.4.5. Market size and forecast, by End User

8.4.6. Market size and forecast, by country

8.4.6.1. Japan

8.4.6.1.1. Market size and forecast, by Product

8.4.6.1.1.1. Japan Consumables Pancreatic Cancer Diagnostic Market by Type

8.4.6.1.2. Market size and forecast, by Test Type

8.4.6.1.3. Market size and forecast, by Cancer Type

8.4.6.1.3.1. Japan Exocrine Pancreatic Cancer Diagnostic Market by Type

8.4.6.1.4. Market size and forecast, by End User

8.4.6.2. China

8.4.6.2.1. Market size and forecast, by Product

8.4.6.2.1.1. China Consumables Pancreatic Cancer Diagnostic Market by Type

8.4.6.2.2. Market size and forecast, by Test Type

8.4.6.2.3. Market size and forecast, by Cancer Type

8.4.6.2.3.1. China Exocrine Pancreatic Cancer Diagnostic Market by Type

8.4.6.2.4. Market size and forecast, by End User

8.4.6.3. India

8.4.6.3.1. Market size and forecast, by Product

8.4.6.3.1.1. India Consumables Pancreatic Cancer Diagnostic Market by Type

8.4.6.3.2. Market size and forecast, by Test Type

8.4.6.3.3. Market size and forecast, by Cancer Type

8.4.6.3.3.1. India Exocrine Pancreatic Cancer Diagnostic Market by Type

8.4.6.3.4. Market size and forecast, by End User

8.4.6.4. Australia

8.4.6.4.1. Market size and forecast, by Product

8.4.6.4.1.1. Australia Consumables Pancreatic Cancer Diagnostic Market by Type

8.4.6.4.2. Market size and forecast, by Test Type

8.4.6.4.3. Market size and forecast, by Cancer Type

8.4.6.4.3.1. Australia Exocrine Pancreatic Cancer Diagnostic Market by Type

8.4.6.4.4. Market size and forecast, by End User

8.4.6.5. South Korea

8.4.6.5.1. Market size and forecast, by Product

8.4.6.5.1.1. South Korea Consumables Pancreatic Cancer Diagnostic Market by Type

8.4.6.5.2. Market size and forecast, by Test Type

8.4.6.5.3. Market size and forecast, by Cancer Type

8.4.6.5.3.1. South Korea Exocrine Pancreatic Cancer Diagnostic Market by Type

8.4.6.5.4. Market size and forecast, by End User

8.4.6.6. Rest of Asia-Pacific

8.4.6.6.1. Market size and forecast, by Product

8.4.6.6.1.1. Rest of Asia-Pacific Consumables Pancreatic Cancer Diagnostic Market by Type

8.4.6.6.2. Market size and forecast, by Test Type

8.4.6.6.3. Market size and forecast, by Cancer Type

8.4.6.6.3.1. Rest of Asia-Pacific Exocrine Pancreatic Cancer Diagnostic Market by Type

8.4.6.6.4. Market size and forecast, by End User

8.5. LAMEA

8.5.1. Key market trends, growth factors and opportunities

8.5.2. Market size and forecast, by Product

8.5.2.1. LAMEA Consumables Pancreatic Cancer Diagnostic Market by Type

8.5.3. Market size and forecast, by Test Type

8.5.4. Market size and forecast, by Cancer Type

8.5.4.1. LAMEA Exocrine Pancreatic Cancer Diagnostic Market by Type

8.5.5. Market size and forecast, by End User

8.5.6. Market size and forecast, by country

8.5.6.1. Brazil

8.5.6.1.1. Market size and forecast, by Product

8.5.6.1.1.1. Brazil Consumables Pancreatic Cancer Diagnostic Market by Type

8.5.6.1.2. Market size and forecast, by Test Type

8.5.6.1.3. Market size and forecast, by Cancer Type

8.5.6.1.3.1. Brazil Exocrine Pancreatic Cancer Diagnostic Market by Type

8.5.6.1.4. Market size and forecast, by End User

8.5.6.2. Saudi Arabia

8.5.6.2.1. Market size and forecast, by Product

8.5.6.2.1.1. Saudi Arabia Consumables Pancreatic Cancer Diagnostic Market by Type

8.5.6.2.2. Market size and forecast, by Test Type

8.5.6.2.3. Market size and forecast, by Cancer Type

8.5.6.2.3.1. Saudi Arabia Exocrine Pancreatic Cancer Diagnostic Market by Type

8.5.6.2.4. Market size and forecast, by End User

8.5.6.3. South Africa

8.5.6.3.1. Market size and forecast, by Product

8.5.6.3.1.1. South Africa Consumables Pancreatic Cancer Diagnostic Market by Type

8.5.6.3.2. Market size and forecast, by Test Type

8.5.6.3.3. Market size and forecast, by Cancer Type

8.5.6.3.3.1. South Africa Exocrine Pancreatic Cancer Diagnostic Market by Type

8.5.6.3.4. Market size and forecast, by End User

8.5.6.4. Rest of LAMEA

8.5.6.4.1. Market size and forecast, by Product

8.5.6.4.1.1. Rest of LAMEA Consumables Pancreatic Cancer Diagnostic Market by Type

8.5.6.4.2. Market size and forecast, by Test Type

8.5.6.4.3. Market size and forecast, by Cancer Type

8.5.6.4.3.1. Rest of LAMEA Exocrine Pancreatic Cancer Diagnostic Market by

Type

8.5.6.4.4. Market size and forecast, by End User

## **CHAPTER 9: COMPETITIVE LANDSCAPE**

9.1. Introduction

9.2. Top winning strategies

9.3. Product mapping of top 10 player

9.4. Competitive dashboard

9.5. Competitive heatmap

9.6. Top player positioning, 2023

## **CHAPTER 10: COMPANY PROFILES**

10.1. Thermo Fisher Scientific Inc.

10.1.1. Company overview

10.1.2. Key executives

10.1.3. Company snapshot

10.1.4. Operating business segments

10.1.5. Product portfolio

10.1.6. Business performance

## 10.2. Qiagen N.V.

- 10.2.1. Company overview
- 10.2.2. Key executives
- 10.2.3. Company snapshot
- 10.2.4. Operating business segments
- 10.2.5. Product portfolio
- 10.2.6. Business performance

## 10.3. F. Hoffmann-La Roche Ltd.

- 10.3.1. Company overview
- 10.3.2. Key executives
- 10.3.3. Company snapshot
- 10.3.4. Operating business segments
- 10.3.5. Product portfolio
- 10.3.6. Business performance

## 10.4. Myriad Genetics, Inc.

- 10.4.1. Company overview
- 10.4.2. Key executives
- 10.4.3. Company snapshot
- 10.4.4. Operating business segments
- 10.4.5. Product portfolio
- 10.4.6. Business performance

## 10.5. Fujifilm Holdings Corporation

- 10.5.1. Company overview
- 10.5.2. Key executives
- 10.5.3. Company snapshot
- 10.5.4. Operating business segments
- 10.5.5. Product portfolio
- 10.5.6. Business performance

## 10.6. Randox Laboratories Ltd.

- 10.6.1. Company overview
- 10.6.2. Key executives
- 10.6.3. Company snapshot
- 10.6.4. Operating business segments
- 10.6.5. Product portfolio

## 10.7. ClearNote Health

- 10.7.1. Company overview
- 10.7.2. Key executives
- 10.7.3. Company snapshot
- 10.7.4. Operating business segments

- 10.7.5. Product portfolio
- 10.7.6. Key strategic moves and developments
- 10.8. Siemens
  - 10.8.1. Company overview
  - 10.8.2. Key executives
  - 10.8.3. Company snapshot
  - 10.8.4. Operating business segments
  - 10.8.5. Product portfolio
  - 10.8.6. Business performance
- 10.9. Prestige Biopharma Ltd.
  - 10.9.1. Company overview
  - 10.9.2. Key executives
  - 10.9.3. Company snapshot
  - 10.9.4. Operating business segments
  - 10.9.5. Product portfolio
- 10.10. Toray Industries, Inc.
  - 10.10.1. Company overview
  - 10.10.2. Key executives
  - 10.10.3. Company snapshot
  - 10.10.4. Operating business segments
  - 10.10.5. Product portfolio
  - 10.10.6. Business performance
  - 10.10.7. Key strategic moves and developments

## List Of Tables

### LIST OF TABLES

TABLE 01. GLOBAL PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (\$MILLION)

TABLE 02. GLOBAL PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (UNITS)

TABLE 03. PANCREATIC CANCER DIAGNOSTIC MARKET FOR INSTRUMENTS, BY REGION, 2023-2035 (\$MILLION)

TABLE 04. PANCREATIC CANCER DIAGNOSTIC MARKET FOR INSTRUMENTS, BY REGION, 2023-2035 (UNITS)

TABLE 05. PANCREATIC CANCER DIAGNOSTIC MARKET FOR CONSUMABLES, BY REGION, 2023-2035 (\$MILLION)

TABLE 06. PANCREATIC CANCER DIAGNOSTIC MARKET FOR CONSUMABLES, BY REGION, 2023-2035 (UNITS)

TABLE 07. GLOBAL CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 08. GLOBAL CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (UNITS)

TABLE 09. PANCREATIC CANCER DIAGNOSTIC MARKET FOR KITS, BY REGION, 2023-2035 (\$MILLION)

TABLE 10. PANCREATIC CANCER DIAGNOSTIC MARKET FOR KITS, BY REGION, 2023-2035 (UNITS)

TABLE 11. PANCREATIC CANCER DIAGNOSTIC MARKET FOR NEEDLES, BY REGION, 2023-2035 (\$MILLION)

TABLE 12. PANCREATIC CANCER DIAGNOSTIC MARKET FOR NEEDLES, BY REGION, 2023-2035 (UNITS)

TABLE 13. PANCREATIC CANCER DIAGNOSTIC MARKET FOR OTHERS, BY REGION, 2023-2035 (\$MILLION)

TABLE 14. PANCREATIC CANCER DIAGNOSTIC MARKET FOR OTHERS, BY REGION, 2023-2035 (UNITS)

TABLE 15. GLOBAL PANCREATIC CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2023-2035 (\$MILLION)

TABLE 16. PANCREATIC CANCER DIAGNOSTIC MARKET FOR IMAGING TEST, BY REGION, 2023-2035 (\$MILLION)

TABLE 17. PANCREATIC CANCER DIAGNOSTIC MARKET FOR BLOOD TEST, BY REGION, 2023-2035 (\$MILLION)

TABLE 18. PANCREATIC CANCER DIAGNOSTIC MARKET FOR BIOPSY, BY REGION, 2023-2035 (\$MILLION)

TABLE 19. GLOBAL PANCREATIC CANCER DIAGNOSTIC MARKET, BY CANCER TYPE , 2023-2035 (\$MILLION)

TABLE 20. PANCREATIC CANCER DIAGNOSTIC MARKET FOR EXOCRINE, BY REGION, 2023-2035 (\$MILLION)

TABLE 21. GLOBAL EXOCRINE PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 22. PANCREATIC CANCER DIAGNOSTIC MARKET FOR ADENOCARCINOMA, BY REGION, 2023-2035 (\$MILLION)

TABLE 23. PANCREATIC CANCER DIAGNOSTIC MARKET FOR ADENOSQUAMOUS CARCINOMA, BY REGION, 2023-2035 (\$MILLION)

TABLE 24. PANCREATIC CANCER DIAGNOSTIC MARKET FOR OTHERS, BY REGION, 2023-2035 (\$MILLION)

TABLE 25. PANCREATIC CANCER DIAGNOSTIC MARKET FOR ENDOCRINE, BY REGION, 2023-2035 (\$MILLION)

TABLE 26. GLOBAL PANCREATIC CANCER DIAGNOSTIC MARKET, BY END USER, 2023-2035 (\$MILLION)

TABLE 27. PANCREATIC CANCER DIAGNOSTIC MARKET FOR HOSPITALS, BY REGION, 2023-2035 (\$MILLION)

TABLE 28. PANCREATIC CANCER DIAGNOSTIC MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2023-2035 (\$MILLION)

TABLE 29. PANCREATIC CANCER DIAGNOSTIC MARKET FOR OTHERS, BY REGION, 2023-2035 (\$MILLION)

TABLE 30. PANCREATIC CANCER DIAGNOSTIC MARKET, BY REGION, 2023-2035 (\$MILLION)

TABLE 31. PANCREATIC CANCER DIAGNOSTIC MARKET, BY REGION, 2023-2035 (UNITS)

TABLE 32. NORTH AMERICA PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (\$MILLION)

TABLE 33. NORTH AMERICA PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (UNITS)

TABLE 34. NORTH AMERICA CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 35. NORTH AMERICA CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (UNITS)

TABLE 36. NORTH AMERICA PANCREATIC CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2023-2035 (\$MILLION)

TABLE 37. NORTH AMERICA PANCREATIC CANCER DIAGNOSTIC MARKET, BY CANCER TYPE , 2023-2035 (\$MILLION)

TABLE 38. NORTH AMERICA EXOCRINE PANCREATIC CANCER DIAGNOSTIC

MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 39. NORTH AMERICA PANCREATIC CANCER DIAGNOSTIC MARKET, BY END USER, 2023-2035 (\$MILLION)

TABLE 40. NORTH AMERICA PANCREATIC CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2023-2035 (\$MILLION)

TABLE 41. NORTH AMERICA PANCREATIC CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2023-2035 (UNITS)

TABLE 42. U.S. PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (\$MILLION)

TABLE 43. U.S. PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (UNITS)

TABLE 44. U.S. CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 45. U.S. CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (UNITS)

TABLE 46. U.S. PANCREATIC CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2023-2035 (\$MILLION)

TABLE 47. U.S. PANCREATIC CANCER DIAGNOSTIC MARKET, BY CANCER TYPE , 2023-2035 (\$MILLION)

TABLE 48. U.S. EXOCRINE PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 49. U.S. PANCREATIC CANCER DIAGNOSTIC MARKET, BY END USER, 2023-2035 (\$MILLION)

TABLE 50. CANADA PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (\$MILLION)

TABLE 51. CANADA PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (UNITS)

TABLE 52. CANADA CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 53. CANADA CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (UNITS)

TABLE 54. CANADA PANCREATIC CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2023-2035 (\$MILLION)

TABLE 55. CANADA PANCREATIC CANCER DIAGNOSTIC MARKET, BY CANCER TYPE , 2023-2035 (\$MILLION)

TABLE 56. CANADA EXOCRINE PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 57. CANADA PANCREATIC CANCER DIAGNOSTIC MARKET, BY END USER, 2023-2035 (\$MILLION)

- TABLE 58. MEXICO PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (\$MILLION)
- TABLE 59. MEXICO PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (UNITS)
- TABLE 60. MEXICO CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)
- TABLE 61. MEXICO CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (UNITS)
- TABLE 62. MEXICO PANCREATIC CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2023-2035 (\$MILLION)
- TABLE 63. MEXICO PANCREATIC CANCER DIAGNOSTIC MARKET, BY CANCER TYPE , 2023-2035 (\$MILLION)
- TABLE 64. MEXICO EXOCRINE PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)
- TABLE 65. MEXICO PANCREATIC CANCER DIAGNOSTIC MARKET, BY END USER, 2023-2035 (\$MILLION)
- TABLE 66. EUROPE PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (\$MILLION)
- TABLE 67. EUROPE PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (UNITS)
- TABLE 68. EUROPE CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)
- TABLE 69. EUROPE CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (UNITS)
- TABLE 70. EUROPE PANCREATIC CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2023-2035 (\$MILLION)
- TABLE 71. EUROPE PANCREATIC CANCER DIAGNOSTIC MARKET, BY CANCER TYPE , 2023-2035 (\$MILLION)
- TABLE 72. EUROPE EXOCRINE PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)
- TABLE 73. EUROPE PANCREATIC CANCER DIAGNOSTIC MARKET, BY END USER, 2023-2035 (\$MILLION)
- TABLE 74. EUROPE PANCREATIC CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2023-2035 (\$MILLION)
- TABLE 75. EUROPE PANCREATIC CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2023-2035 (UNITS)
- TABLE 76. GERMANY PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (\$MILLION)
- TABLE 77. GERMANY PANCREATIC CANCER DIAGNOSTIC MARKET, BY

PRODUCT, 2023-2035 (UNITS)

TABLE 78. GERMANY CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 79. GERMANY CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (UNITS)

TABLE 80. GERMANY PANCREATIC CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2023-2035 (\$MILLION)

TABLE 81. GERMANY PANCREATIC CANCER DIAGNOSTIC MARKET, BY CANCER TYPE , 2023-2035 (\$MILLION)

TABLE 82. GERMANY EXOCRINE PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 83. GERMANY PANCREATIC CANCER DIAGNOSTIC MARKET, BY END USER, 2023-2035 (\$MILLION)

TABLE 84. FRANCE PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (\$MILLION)

TABLE 85. FRANCE PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (UNITS)

TABLE 86. FRANCE CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 87. FRANCE CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (UNITS)

TABLE 88. FRANCE PANCREATIC CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2023-2035 (\$MILLION)

TABLE 89. FRANCE PANCREATIC CANCER DIAGNOSTIC MARKET, BY CANCER TYPE , 2023-2035 (\$MILLION)

TABLE 90. FRANCE EXOCRINE PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 91. FRANCE PANCREATIC CANCER DIAGNOSTIC MARKET, BY END USER, 2023-2035 (\$MILLION)

TABLE 92. UK PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (\$MILLION)

TABLE 93. UK PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (UNITS)

TABLE 94. UK CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 95. UK CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (UNITS)

TABLE 96. UK PANCREATIC CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2023-2035 (\$MILLION)

TABLE 97. UK PANCREATIC CANCER DIAGNOSTIC MARKET, BY CANCER TYPE , 2023-2035 (\$MILLION)

TABLE 98. UK EXOCRINE PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 99. UK PANCREATIC CANCER DIAGNOSTIC MARKET, BY END USER, 2023-2035 (\$MILLION)

TABLE 100. ITALY PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (\$MILLION)

TABLE 101. ITALY PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (UNITS)

TABLE 102. ITALY CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 103. ITALY CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (UNITS)

TABLE 104. ITALY PANCREATIC CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2023-2035 (\$MILLION)

TABLE 105. ITALY PANCREATIC CANCER DIAGNOSTIC MARKET, BY CANCER TYPE , 2023-2035 (\$MILLION)

TABLE 106. ITALY EXOCRINE PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 107. ITALY PANCREATIC CANCER DIAGNOSTIC MARKET, BY END USER, 2023-2035 (\$MILLION)

TABLE 108. SPAIN PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (\$MILLION)

TABLE 109. SPAIN PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (UNITS)

TABLE 110. SPAIN CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 111. SPAIN CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (UNITS)

TABLE 112. SPAIN PANCREATIC CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2023-2035 (\$MILLION)

TABLE 113. SPAIN PANCREATIC CANCER DIAGNOSTIC MARKET, BY CANCER TYPE , 2023-2035 (\$MILLION)

TABLE 114. SPAIN EXOCRINE PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 115. SPAIN PANCREATIC CANCER DIAGNOSTIC MARKET, BY END USER, 2023-2035 (\$MILLION)

TABLE 116. REST OF EUROPE PANCREATIC CANCER DIAGNOSTIC MARKET, BY

PRODUCT, 2023-2035 (\$MILLION)

TABLE 117. REST OF EUROPE PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (UNITS)

TABLE 118. REST OF EUROPE CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 119. REST OF EUROPE CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (UNITS)

TABLE 120. REST OF EUROPE PANCREATIC CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2023-2035 (\$MILLION)

TABLE 121. REST OF EUROPE PANCREATIC CANCER DIAGNOSTIC MARKET, BY CANCER TYPE , 2023-2035 (\$MILLION)

TABLE 122. REST OF EUROPE EXOCRINE PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 123. REST OF EUROPE PANCREATIC CANCER DIAGNOSTIC MARKET, BY END USER, 2023-2035 (\$MILLION)

TABLE 124. ASIA-PACIFIC PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (\$MILLION)

TABLE 125. ASIA-PACIFIC PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (UNITS)

TABLE 126. ASIA-PACIFIC CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 127. ASIA-PACIFIC CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (UNITS)

TABLE 128. ASIA-PACIFIC PANCREATIC CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2023-2035 (\$MILLION)

TABLE 129. ASIA-PACIFIC PANCREATIC CANCER DIAGNOSTIC MARKET, BY CANCER TYPE , 2023-2035 (\$MILLION)

TABLE 130. ASIA-PACIFIC EXOCRINE PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 131. ASIA-PACIFIC PANCREATIC CANCER DIAGNOSTIC MARKET, BY END USER, 2023-2035 (\$MILLION)

TABLE 132. ASIA-PACIFIC PANCREATIC CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2023-2035 (\$MILLION)

TABLE 133. ASIA-PACIFIC PANCREATIC CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2023-2035 (UNITS)

TABLE 134. JAPAN PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (\$MILLION)

TABLE 135. JAPAN PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (UNITS)

TABLE 136. JAPAN CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 137. JAPAN CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (UNITS)

TABLE 138. JAPAN PANCREATIC CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2023-2035 (\$MILLION)

TABLE 139. JAPAN PANCREATIC CANCER DIAGNOSTIC MARKET, BY CANCER TYPE , 2023-2035 (\$MILLION)

TABLE 140. JAPAN EXOCRINE PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 141. JAPAN PANCREATIC CANCER DIAGNOSTIC MARKET, BY END USER, 2023-2035 (\$MILLION)

TABLE 142. CHINA PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (\$MILLION)

TABLE 143. CHINA PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (UNITS)

TABLE 144. CHINA CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 145. CHINA CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (UNITS)

TABLE 146. CHINA PANCREATIC CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2023-2035 (\$MILLION)

TABLE 147. CHINA PANCREATIC CANCER DIAGNOSTIC MARKET, BY CANCER TYPE , 2023-2035 (\$MILLION)

TABLE 148. CHINA EXOCRINE PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 149. CHINA PANCREATIC CANCER DIAGNOSTIC MARKET, BY END USER, 2023-2035 (\$MILLION)

TABLE 150. INDIA PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (\$MILLION)

TABLE 151. INDIA PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (UNITS)

TABLE 152. INDIA CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 153. INDIA CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (UNITS)

TABLE 154. INDIA PANCREATIC CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2023-2035 (\$MILLION)

TABLE 155. INDIA PANCREATIC CANCER DIAGNOSTIC MARKET, BY CANCER

TYPE , 2023-2035 (\$MILLION)

TABLE 156. INDIA EXOCRINE PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 157. INDIA PANCREATIC CANCER DIAGNOSTIC MARKET, BY END USER, 2023-2035 (\$MILLION)

TABLE 158. AUSTRALIA PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (\$MILLION)

TABLE 159. AUSTRALIA PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (UNITS)

TABLE 160. AUSTRALIA CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 161. AUSTRALIA CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (UNITS)

TABLE 162. AUSTRALIA PANCREATIC CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2023-2035 (\$MILLION)

TABLE 163. AUSTRALIA PANCREATIC CANCER DIAGNOSTIC MARKET, BY CANCER TYPE , 2023-2035 (\$MILLION)

TABLE 164. AUSTRALIA EXOCRINE PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 165. AUSTRALIA PANCREATIC CANCER DIAGNOSTIC MARKET, BY END USER, 2023-2035 (\$MILLION)

TABLE 166. SOUTH KOREA PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (\$MILLION)

TABLE 167. SOUTH KOREA PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (UNITS)

TABLE 168. SOUTH KOREA CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 169. SOUTH KOREA CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (UNITS)

TABLE 170. SOUTH KOREA PANCREATIC CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2023-2035 (\$MILLION)

TABLE 171. SOUTH KOREA PANCREATIC CANCER DIAGNOSTIC MARKET, BY CANCER TYPE , 2023-2035 (\$MILLION)

TABLE 172. SOUTH KOREA EXOCRINE PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 173. SOUTH KOREA PANCREATIC CANCER DIAGNOSTIC MARKET, BY END USER, 2023-2035 (\$MILLION)

TABLE 174. REST OF ASIA-PACIFIC PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (\$MILLION)

- TABLE 175. REST OF ASIA-PACIFIC PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (UNITS)
- TABLE 176. REST OF ASIA-PACIFIC CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)
- TABLE 177. REST OF ASIA-PACIFIC CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (UNITS)
- TABLE 178. REST OF ASIA-PACIFIC PANCREATIC CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2023-2035 (\$MILLION)
- TABLE 179. REST OF ASIA-PACIFIC PANCREATIC CANCER DIAGNOSTIC MARKET, BY CANCER TYPE , 2023-2035 (\$MILLION)
- TABLE 180. REST OF ASIA-PACIFIC EXOCRINE PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)
- TABLE 181. REST OF ASIA-PACIFIC PANCREATIC CANCER DIAGNOSTIC MARKET, BY END USER, 2023-2035 (\$MILLION)
- TABLE 182. LAMEA PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (\$MILLION)
- TABLE 183. LAMEA PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (UNITS)
- TABLE 184. LAMEA CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)
- TABLE 185. LAMEA CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (UNITS)
- TABLE 186. LAMEA PANCREATIC CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2023-2035 (\$MILLION)
- TABLE 187. LAMEA PANCREATIC CANCER DIAGNOSTIC MARKET, BY CANCER TYPE , 2023-2035 (\$MILLION)
- TABLE 188. LAMEA EXOCRINE PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)
- TABLE 189. LAMEA PANCREATIC CANCER DIAGNOSTIC MARKET, BY END USER, 2023-2035 (\$MILLION)
- TABLE 190. LAMEA PANCREATIC CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2023-2035 (\$MILLION)
- TABLE 191. LAMEA PANCREATIC CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2023-2035 (UNITS)
- TABLE 192. BRAZIL PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (\$MILLION)
- TABLE 193. BRAZIL PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (UNITS)
- TABLE 194. BRAZIL CONSUMABLES PANCREATIC CANCER DIAGNOSTIC

MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 195. BRAZIL CONSUMABLES PANCREATIC CANCER DIAGNOSTIC

MARKET, BY TYPE, 2023-2035 (UNITS)

TABLE 196. BRAZIL PANCREATIC CANCER DIAGNOSTIC MARKET, BY TEST  
TYPE, 2023-2035 (\$MILLION)

TABLE 197. BRAZIL PANCREATIC CANCER DIAGNOSTIC MARKET, BY CANCER  
TYPE , 2023-2035 (\$MILLION)

TABLE 198. BRAZIL EXOCRINE PANCREATIC CANCER DIAGNOSTIC MARKET, BY  
TYPE, 2023-2035 (\$MILLION)

TABLE 199. BRAZIL PANCREATIC CANCER DIAGNOSTIC MARKET, BY END USER,  
2023-2035 (\$MILLION)

TABLE 200. SAUDI ARABIA PANCREATIC CANCER DIAGNOSTIC MARKET, BY  
PRODUCT, 2023-2035 (\$MILLION)

TABLE 201. SAUDI ARABIA PANCREATIC CANCER DIAGNOSTIC MARKET, BY  
PRODUCT, 2023-2035 (UNITS)

TABLE 202. SAUDI ARABIA CONSUMABLES PANCREATIC CANCER DIAGNOSTIC  
MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 203. SAUDI ARABIA CONSUMABLES PANCREATIC CANCER DIAGNOSTIC  
MARKET, BY TYPE, 2023-2035 (UNITS)

TABLE 204. SAUDI ARABIA PANCREATIC CANCER DIAGNOSTIC MARKET, BY  
TEST TYPE, 2023-2035 (\$MILLION)

TABLE 205. SAUDI ARABIA PANCREATIC CANCER DIAGNOSTIC MARKET, BY  
CANCER TYPE , 2023-2035 (\$MILLION)

TABLE 206. SAUDI ARABIA EXOCRINE PANCREATIC CANCER DIAGNOSTIC  
MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 207. SAUDI ARABIA PANCREATIC CANCER DIAGNOSTIC MARKET, BY  
END USER, 2023-2035 (\$MILLION)

TABLE 208. SOUTH AFRICA PANCREATIC CANCER DIAGNOSTIC MARKET, BY  
PRODUCT, 2023-2035 (\$MILLION)

TABLE 209. SOUTH AFRICA PANCREATIC CANCER DIAGNOSTIC MARKET, BY  
PRODUCT, 2023-2035 (UNITS)

TABLE 210. SOUTH AFRICA CONSUMABLES PANCREATIC CANCER DIAGNOSTIC  
MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 211. SOUTH AFRICA CONSUMABLES PANCREATIC CANCER DIAGNOSTIC  
MARKET, BY TYPE, 2023-2035 (UNITS)

TABLE 212. SOUTH AFRICA PANCREATIC CANCER DIAGNOSTIC MARKET, BY  
TEST TYPE, 2023-2035 (\$MILLION)

TABLE 213. SOUTH AFRICA PANCREATIC CANCER DIAGNOSTIC MARKET, BY  
CANCER TYPE , 2023-2035 (\$MILLION)

TABLE 214. SOUTH AFRICA EXOCRINE PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 215. SOUTH AFRICA PANCREATIC CANCER DIAGNOSTIC MARKET, BY END USER, 2023-2035 (\$MILLION)

TABLE 216. REST OF LAMEA PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (\$MILLION)

TABLE 217. REST OF LAMEA PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023-2035 (UNITS)

TABLE 218. REST OF LAMEA CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 219. REST OF LAMEA CONSUMABLES PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (UNITS)

TABLE 220. REST OF LAMEA PANCREATIC CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2023-2035 (\$MILLION)

TABLE 221. REST OF LAMEA PANCREATIC CANCER DIAGNOSTIC MARKET, BY CANCER TYPE , 2023-2035 (\$MILLION)

TABLE 222. REST OF LAMEA EXOCRINE PANCREATIC CANCER DIAGNOSTIC MARKET, BY TYPE, 2023-2035 (\$MILLION)

TABLE 223. REST OF LAMEA PANCREATIC CANCER DIAGNOSTIC MARKET, BY END USER, 2023-2035 (\$MILLION)

TABLE 224. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES

TABLE 225. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT

TABLE 226. THERMO FISHER SCIENTIFIC INC.: PRODUCT SEGMENTS

TABLE 227. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO

TABLE 228. QIAGEN N.V.: KEY EXECUTIVES

TABLE 229. QIAGEN N.V.: COMPANY SNAPSHOT

TABLE 230. QIAGEN N.V.: PRODUCT SEGMENTS

TABLE 231. QIAGEN N.V.: PRODUCT PORTFOLIO

TABLE 232. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES

TABLE 233. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT

TABLE 234. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS

TABLE 235. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO

TABLE 236. MYRIAD GENETICS, INC.: KEY EXECUTIVES

TABLE 237. MYRIAD GENETICS, INC.: COMPANY SNAPSHOT

TABLE 238. MYRIAD GENETICS, INC.: PRODUCT SEGMENTS

TABLE 239. MYRIAD GENETICS, INC.: SERVICE SEGMENTS

TABLE 240. MYRIAD GENETICS, INC.: PRODUCT PORTFOLIO

TABLE 241. FUJIFILM HOLDINGS CORPORATION: KEY EXECUTIVES

TABLE 242. FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT

TABLE 243. FUJIFILM HOLDINGS CORPORATION: PRODUCT SEGMENTS  
TABLE 244. FUJIFILM HOLDINGS CORPORATION: PRODUCT PORTFOLIO  
TABLE 245. RANDOX LABORATORIES LTD.: KEY EXECUTIVES  
TABLE 246. RANDOX LABORATORIES LTD.: COMPANY SNAPSHOT  
TABLE 247. RANDOX LABORATORIES LTD.: PRODUCT SEGMENTS  
TABLE 248. RANDOX LABORATORIES LTD.: PRODUCT PORTFOLIO  
TABLE 249. CLEARNOTE HEALTH: KEY EXECUTIVES  
TABLE 250. CLEARNOTE HEALTH: COMPANY SNAPSHOT  
TABLE 251. CLEARNOTE HEALTH: PRODUCT SEGMENTS  
TABLE 252. CLEARNOTE HEALTH: PRODUCT PORTFOLIO  
TABLE 253. CLEARNOTE HEALTH: KEY STRATEGIES  
TABLE 254. SIEMENS: KEY EXECUTIVES  
TABLE 255. SIEMENS: COMPANY SNAPSHOT  
TABLE 256. SIEMENS: PRODUCT SEGMENTS  
TABLE 257. SIEMENS: PRODUCT PORTFOLIO  
TABLE 258. PRESTIGE BIOPHARMA LTD.: KEY EXECUTIVES  
TABLE 259. PRESTIGE BIOPHARMA LTD.: COMPANY SNAPSHOT  
TABLE 260. PRESTIGE BIOPHARMA LTD.: PRODUCT SEGMENTS  
TABLE 261. PRESTIGE BIOPHARMA LTD.: PRODUCT PORTFOLIO  
TABLE 262. TORAY INDUSTRIES, INC.: KEY EXECUTIVES  
TABLE 263. TORAY INDUSTRIES, INC.: COMPANY SNAPSHOT  
TABLE 264. TORAY INDUSTRIES, INC.: PRODUCT SEGMENTS  
TABLE 265. TORAY INDUSTRIES, INC.: PRODUCT PORTFOLIO  
TABLE 266. TORAY INDUSTRIES, INC.: KEY STRATEGIES

## List Of Figures

### LIST OF FIGURES

FIGURE 01. PANCREATIC CANCER DIAGNOSTIC MARKET, 2023-2035

FIGURE 02. SEGMENTATION OF PANCREATIC CANCER DIAGNOSTIC MARKET, 2023-2035

FIGURE 03. TOP IMPACTING FACTORS IN PANCREATIC CANCER DIAGNOSTIC MARKET (2023 TO 2035)

FIGURE 04. TOP INVESTMENT POCKETS IN PANCREATIC CANCER DIAGNOSTIC MARKET (2024-2035)

FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS

FIGURE 06. MODERATE THREAT OF NEW ENTRANTS

FIGURE 07. MODERATE THREAT OF SUBSTITUTES

FIGURE 08. MODERATE INTENSITY OF RIVALRY

FIGURE 09. MODERATE BARGAINING POWER OF BUYERS

FIGURE 10. GLOBAL PANCREATIC CANCER DIAGNOSTIC MARKET: DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 11. PANCREATIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2023 AND 2035(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PANCREATIC CANCER DIAGNOSTIC MARKET FOR INSTRUMENTS, BY COUNTRY 2023 AND 2035(%)

FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PANCREATIC CANCER DIAGNOSTIC MARKET FOR CONSUMABLES, BY COUNTRY 2023 AND 2035(%)

FIGURE 14. PANCREATIC CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2023 AND 2035(%)

FIGURE 15. COMPARATIVE SHARE ANALYSIS OF PANCREATIC CANCER DIAGNOSTIC MARKET FOR IMAGING TEST, BY COUNTRY 2023 AND 2035(%)

FIGURE 16. COMPARATIVE SHARE ANALYSIS OF PANCREATIC CANCER DIAGNOSTIC MARKET FOR BLOOD TEST, BY COUNTRY 2023 AND 2035(%)

FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PANCREATIC CANCER DIAGNOSTIC MARKET FOR BIOPSY, BY COUNTRY 2023 AND 2035(%)

FIGURE 18. PANCREATIC CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2023 AND 2035(%)

FIGURE 19. COMPARATIVE SHARE ANALYSIS OF PANCREATIC CANCER DIAGNOSTIC MARKET FOR EXOCRINE, BY COUNTRY 2023 AND 2035(%)

FIGURE 20. COMPARATIVE SHARE ANALYSIS OF PANCREATIC CANCER DIAGNOSTIC MARKET FOR ENDOCRINE, BY COUNTRY 2023 AND 2035(%)

FIGURE 21. PANCREATIC CANCER DIAGNOSTIC MARKET, BY END USER, 2023 AND 2035(%)

FIGURE 22. COMPARATIVE SHARE ANALYSIS OF PANCREATIC CANCER DIAGNOSTIC MARKET FOR HOSPITALS, BY COUNTRY 2023 AND 2035(%)

FIGURE 23. COMPARATIVE SHARE ANALYSIS OF PANCREATIC CANCER DIAGNOSTIC MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY 2023 AND 2035(%)

FIGURE 24. COMPARATIVE SHARE ANALYSIS OF PANCREATIC CANCER DIAGNOSTIC MARKET FOR OTHERS, BY COUNTRY 2023 AND 2035(%)

FIGURE 25. PANCREATIC CANCER DIAGNOSTIC MARKET BY REGION, 2023 AND 2035(%)

FIGURE 26. U.S. PANCREATIC CANCER DIAGNOSTIC MARKET, 2023-2035 (\$MILLION)

FIGURE 27. CANADA PANCREATIC CANCER DIAGNOSTIC MARKET, 2023-2035 (\$MILLION)

FIGURE 28. MEXICO PANCREATIC CANCER DIAGNOSTIC MARKET, 2023-2035 (\$MILLION)

FIGURE 29. GERMANY PANCREATIC CANCER DIAGNOSTIC MARKET, 2023-2035 (\$MILLION)

FIGURE 30. FRANCE PANCREATIC CANCER DIAGNOSTIC MARKET, 2023-2035 (\$MILLION)

FIGURE 31. UK PANCREATIC CANCER DIAGNOSTIC MARKET, 2023-2035 (\$MILLION)

FIGURE 32. ITALY PANCREATIC CANCER DIAGNOSTIC MARKET, 2023-2035 (\$MILLION)

FIGURE 33. SPAIN PANCREATIC CANCER DIAGNOSTIC MARKET, 2023-2035 (\$MILLION)

FIGURE 34. REST OF EUROPE PANCREATIC CANCER DIAGNOSTIC MARKET, 2023-2035 (\$MILLION)

FIGURE 35. JAPAN PANCREATIC CANCER DIAGNOSTIC MARKET, 2023-2035 (\$MILLION)

FIGURE 36. CHINA PANCREATIC CANCER DIAGNOSTIC MARKET, 2023-2035 (\$MILLION)

FIGURE 37. INDIA PANCREATIC CANCER DIAGNOSTIC MARKET, 2023-2035 (\$MILLION)

FIGURE 38. AUSTRALIA PANCREATIC CANCER DIAGNOSTIC MARKET, 2023-2035 (\$MILLION)

FIGURE 39. SOUTH KOREA PANCREATIC CANCER DIAGNOSTIC MARKET, 2023-2035 (\$MILLION)

FIGURE 40. REST OF ASIA-PACIFIC PANCREATIC CANCER DIAGNOSTIC MARKET, 2023-2035 (\$MILLION)

FIGURE 41. BRAZIL PANCREATIC CANCER DIAGNOSTIC MARKET, 2023-2035 (\$MILLION)

FIGURE 42. SAUDI ARABIA PANCREATIC CANCER DIAGNOSTIC MARKET, 2023-2035 (\$MILLION)

FIGURE 43. SOUTH AFRICA PANCREATIC CANCER DIAGNOSTIC MARKET, 2023-2035 (\$MILLION)

FIGURE 44. REST OF LAMEA PANCREATIC CANCER DIAGNOSTIC MARKET, 2023-2035 (\$MILLION)

FIGURE 45. TOP WINNING STRATEGIES, BY YEAR (2023-2024)

FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT (2023-2024)

FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY (2023-2024)

FIGURE 48. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 49. COMPETITIVE DASHBOARD

FIGURE 50. COMPETITIVE HEATMAP: PANCREATIC CANCER DIAGNOSTIC MARKET

FIGURE 51. TOP PLAYER POSITIONING, 2023

FIGURE 52. THERMO FISHER SCIENTIFIC INC.: NET REVENUE, 2022-2024 (\$MILLION)

FIGURE 53. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY SEGMENT, 2024 (%)

FIGURE 54. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY REGION, 2024 (%)

FIGURE 55. QIAGEN N.V.: NET REVENUE, 2021-2023 (\$MILLION)

FIGURE 56. QIAGEN N.V.: REVENUE SHARE BY REGION, 2023 (%)

FIGURE 57. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2022-2024 (\$MILLION)

FIGURE 58. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2024 (%)

FIGURE 59. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2024 (%)

FIGURE 60. MYRIAD GENETICS, INC.: NET REVENUE, 2022-2024 (\$MILLION)

FIGURE 61. MYRIAD GENETICS, INC.: REVENUE SHARE BY REGION, 2024 (%)

FIGURE 62. FUJIFILM HOLDINGS CORPORATION: NET REVENUE, 2021-2023 (\$MILLION)

FIGURE 63. FUJIFILM HOLDINGS CORPORATION: REVENUE SHARE BY SEGMENT, 2023 (%)

FIGURE 64. FUJIFILM HOLDINGS CORPORATION: REVENUE SHARE BY REGION, 2023 (%)

FIGURE 65. SIEMENS: NET REVENUE, 2021-2023 (\$MILLION)

FIGURE 66. SIEMENS: REVENUE SHARE BY SEGMENT, 2023 (%)

FIGURE 67. SIEMENS: REVENUE SHARE BY REGION, 2023 (%)

FIGURE 68. TORAY INDUSTRIES, INC.: NET REVENUE, 2021-2023 (\$MILLION)

FIGURE 69. TORAY INDUSTRIES, INC.: REVENUE SHARE BY SEGMENT, 2023 (%)

FIGURE 70. TORAY INDUSTRIES, INC.: REVENUE SHARE BY REGION, 2023 (%)

## I would like to order

Product name: Pancreatic Cancer Diagnostic Market By Product (Instruments, Consumables), By Test Type (Imaging Test, Blood Test, Biopsy), By Cancer Type (Exocrine, Endocrine), By End User (Hospitals, Diagnostic Centers, Others): Global Opportunity Analysis and Industry Forecast, 2024-2035

Product link: <https://marketpublishers.com/r/P16AE735A872EN.html>

Price: US\$ 2,655.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P16AE735A872EN.html>